Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs Novavax Inc (NVAX) Price & Performance

Indivior Pharmaceuticals Inc. Common StockTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Indivior Pharmaceuticals Inc. Common Stock vs Novavax Inc — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.01 (market cap $4.18B), while Novavax Inc trades at $12.45 (market cap $2.11B). The key difference: Indivior Pharmaceuticals Inc. Common Stock is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Indivior Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.

INDVNVAX
Market Cap
$4.18B$2.11B
Volume
1,819,7468,376,831
Sector
HealthHealth
52-Week High
$41.83$12.82
52-Week Low
$24.09$6.22
Typical Hold Time
0 Days59 Days
Enterprise Value
$4.47B$1.69B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Indivior Pharmaceuticals Inc. Common Stock

No Aura AI signal available yet.

Novavax Inc

Novavax (NVAX) trades at $12.64, down slightly by 0.16% on the day. The stock shows a bullish technical signal with strong moving average and oscillator support. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of -$0.32 surpassing the -$0.38 estimate. The company is transitioning its business model toward a partnership-driven approach centered on its Matrix-M adjuvant technology, with recent regulatory approvals for its updated COVID-19 vaccine in major markets.

The outlook is mixed with strong analyst buy ratings (73.9%) and recent business developments providing catalysts, but significant financial risks remain including negative cash flows, high debt levels, and inconsistent profitability. Investment opportunity exists in the partnership strategy execution, while risks include execution challenges and competitive pressures in the vaccine market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INDV
100% Buy0% Sell
Avg holding period · 0 Days
NVAX
28% Buy72% Sell
Avg holding period · 59 Days

About Indivior Pharmaceuticals Inc. Common Stock

Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.

Read more on INDV →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →